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Abstract
Background: Namilumab (AMG203) is an immunoglobulin G1 monoclonal antibody that binds with high affinity
to the GM-CSF ligand. This was a phase 1b, randomized, double-blind study (PRIORA) to assess namilumab
in active, mild-to-moderate rheumatoid arthritis (RA). The primary outcome was the safety and tolerability of
repeated subcutaneous injections of namilumab in patients with mild-to-moderate RA.
Methods: Adults with mild-to-moderate RA on stable methotrexate doses for ≥12 weeks were eligible.
Patients received three subcutaneous injections of namilumab 150 or 300 mg, or placebo on days 1, 15,
and 29, with 12 weeks’ follow-up. Primary objective was safety/tolerability.
Results: Patients in cohort 1 were randomized to namilumab 150 mg (n = 8) or placebo (n = 5). In cohort 2,
patients were randomized to namilumab 300 mg (n = 7) or placebo (n = 4). Incidence of treatment-emergent
adverse events (TEAEs) was similar across the three groups (namilumab 150 mg: 63%; namilumab 300 mg:
57%; placebo: 56%). TEAEs in ≥10% of patients were nasopharyngitis (17%) and exacerbation/worsening of
RA (13%). No anti-namilumab antibodies were detected. The pharmacokinetics of namilumab were linear
and typical of a monoclonal antibody with subcutaneous administration. In a post hoc efficacy, per protocol
analysis (n = 21), patients randomized to namilumab showed greater improvement in Disease Activity Score
28 (erythrocyte sedimentation rate and C-reactive protein [CRP]), swelling joint counts and tender joint counts
compared with placebo. Difference in mean DAS28-CRP changes from baseline between namilumab and
placebo favored namilumab at both doses and at all time points. In addition area under the curve for
DAS28-CRP was analyzed as time-adjusted mean change from baseline. A significant improvement in DAS28-
CRP was shown with namilumab (150 and 300 mg groups combined) compared with placebo at day 43
(p = 0.0117) and also 8 weeks after last dosing at day 99 (p = 0.0154).
Conclusions: Subcutaneous namilumab was generally well tolerated. Although namilumab demonstrated
preliminary evidence of efficacy, patient numbers were small; phase 2 studies are ongoing.
Trial registration: ClinicalTrials.gov, NCT01317797. Registered 18 February 2011.
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Background
Rheumatoid arthritis (RA) is a complex, chronic, auto-
immune disease characterized by joint inflammation
leading to erosions of articular cartilage and subchondral
bone [1, 2]. Despite advances in treatment with biologic
disease-modifying antirheumatic drugs (DMARDs), a
significant proportion of RA patients are still not
adequately controlled. For example, most patients
treated with biologic DMARDs do not achieve 50% or
70% improvement according to the American College
of Rheumatology criteria (ACR50 or ACR70 re-
sponses). Only a small proportion of patients achieve
remission with biologic DMARDs, and responses are
often not durable, necessitating frequent treatment
switching [3, 4]. This lack of adequate disease control
indicates a need for new therapies with innovative
mechanisms of action for those patients who fail to
achieve remission or low disease activity, developing
resistance to treatment response, or experience
significant toxicities with current therapy.
Granulocyte macrophage colony-stimulating factor
(GM-CSF) is a hematopoietic growth factor produced by
a number of different cell types, including: T cells, mac-
rophages, mast cells, endothelial cells, smooth muscle
cells, epithelial cells, and fibroblasts [5–8]. GM-CSF
stimulates the proliferation and activation of mature
myeloid cells inducing the production of inflammatory
molecules, thereby acting as a pro-inflammatory cyto-
kine [6]. As GM-CSF is a key activator of the innate
immune system, it is likely to play an important role in
the pathogenesis of autoimmune inflammatory diseases
(including RA) in which macrophages, neutrophils, gran-
ulocytes, eosinophils, and dendritic cells contribute to
disease progression [5, 9, 10]. In patients with RA, GM-
CSF is aberrantly overproduced [11–15]; GM-CSF levels
are moderately elevated in the plasma and highly ele-
vated in the synovial fluid [14, 16], particularly in the
pannus at sites of cartilage erosion [17]. The contribu-
tion of GM-CSF to the development of RA has also been
documented in various in vitro and in vivo mouse
models [18–23]. Moreover, exacerbation of RA disease
activity has been reported in patients receiving GM-CSF
as supportive therapy to resolve neutropenia in Felty’s
syndrome or post-chemotherapy [24, 25].
The central role of GM-CSF in immune responses and
its involvement in autoimmune inflammatory diseases
supports the rationale for GM-CSF-targeted therapy as a
novel treatment approach for RA. Proof-of-concept for
GM-CSF-targeted therapy has been demonstrated for
antibodies targeting the GM-CSF receptor and soluble
GM-CSF [26–31].
Namilumab (AMG203) is a human immunoglobulin
G1 (IgG1) monoclonal antibody that binds with high
affinity to the GM-CSF ligand, potently neutralizing
GM-CSF [32]. Preclinical data showed that a surrogate
mouse antibody of namilumab (22E9) neutralized GM-
CSF, suppressed inflammation, and protected cartilage in
an arthritis mouse model [33]. In a first-in-human study,
healthy volunteers showed that namilumab (single doses
up to 8.0 mg/kg) were generally well tolerated [34].
This phase 1b, first-in-patient, multicenter, random-
ized, double-blind, placebo-controlled, dose-escalation
study assessed the safety, tolerability, pharmacokinetic
(PK) and pharmacodynamic (PD) characteristics and
preliminary efficacy of repeated subcutaneous injections
of namilumab in patients with active mild-to-moderate
RA on stable doses of methotrexate.
Methods
Patients
Patients aged ≥18 years, diagnosed with active RA (ac-
cording to ACR 1987 revised criteria), on stable doses of
methotrexate (≥7.5– ≤ 25 mg/week) for at least 12 weeks
before the first dose of study drug and with low-to-
moderate disease activity (Disease Activity Score 28
[DAS28]-erythrocyte sedimentation rate [ESR] ≥2.6– ≤
5.1) were included. Concomitant nonsteroidal anti-
inflammatory drugs (NSAIDs) with appropriate gastro-
protection, low-dose corticosteroids (≤10 mg prednisone
equivalence per day) and hydroxychloroquine (≤400 mg/
day) were permitted at stable doses for at least 4 weeks
prior to the first dose of study drug.
Exclusion criteria included: unstable RA disease status
with flares; significant extra-articular manifestations of
RA (e.g., pulmonary fibrosis or vasculitis); use of other
DMARDs except methotrexate; and presence or history
of major chronic inflammatory autoimmune diseases
(such as psoriasis, inflammatory bowel disease or sys-
temic lupus erythematosus). Patients with a medical his-
tory of methotrexate-associated lung toxicity, a history
of severe pulmonary disease, and a clinically relevant de-
crease in lung function (forced expiratory volume in 1 sec-
ond [FEV1] <70% of the predicted value) were also
excluded from the study since GM-CSF inhibition could
affect alveolar macrophage function and surfactant
homeostasis in the lung (see Discussion section) [34, 35].
Previous use of GM-CSF and/or granulocyte colony-
stimulating factor and concomitant medication (except
methotrexate, NSAIDs, low-dose corticosteroids, and
hydroxychloroquine) was not permitted.
Study design
Patients received a single subcutaneous injection of
namilumab or placebo on days 1, 15, and 29, in addition
to continued treatment with methotrexate. Two dose
levels of namilumab were evaluated: 150 mg (cohort 1)
and 300 mg (cohort 2). Patients were followed for
Huizinga et al. Arthritis Research & Therapy  (2017) 19:53 Page 2 of 10
approximately 12 weeks after the last dose of study drug
(Additional file 1: Figure S1).
Institutional review boards/ethics committees at the
participating investigational centers approved the study,
which was conducted according to the principles set out
in the Declaration of Helsinki, International Conference
on Harmonisation Guidelines for Good Clinical Practice,
and additional local regulations.
Objectives and assessments
The primary objective was to evaluate the safety and
tolerability of repeated subcutaneous injections of
namilumab in patients with mild-to-moderate RA.
Secondary objectives included evaluation of PK and
PD (namilumab/GM-CSF complexes), including ex-
plorative biomarker assessments and immunogenicity.
Clinical efficacy was an exploratory objective. A pre-
defined, post hoc efficacy analysis was also performed
on the PRIORA data to evaluate the clinical effects of
namilumab on the signs and symptoms of RA (see
Statistical analyses section).
Safety was assessed by adverse events (AEs); clinical
laboratory parameters, urinalysis, electrocardiogram
(ECG), vital signs, pulmonary function tests (FEV1,
forced vital capacity [FVC] and peak flow at specified
time points); and physical examination. Anti-namilumab
antibodies were quantified using a bridging electroche-
miluminescence assay. PD assessments included analysis
of namilumab/GM-CSF complexes, as well as assess-
ment of peripheral blood cytokines and other markers of
inflammation.
In the initial analysis, the exploratory objective of effi-
cacy was assessed using ACR20 and DAS44-ESR. In the
post hoc efficacy analysis, DAS28-C-reactive protein
(DAS28-CRP), DAS28-ESR, tender joint count (TJC; 68
joints), swollen joint count (SJC; 66 joints) and patient’s
global disease activity (100 mm visual analog scale
[VAS]) were evaluated in a per protocol population. In
order to minimize the bias in the post hoc efficacy ana-
lysis, the statistical analysis plan and the criteria for the
per protocol population were specified prior to the ana-
lysis. CRP was quantified at a central laboratory, while
ESR was measured locally.
Statistical analyses
Safety, PD and efficacy populations included all patients
who received namilumab or placebo; and for whom
safety, tolerability or efficacy data were available. The PK
population included all patients who received at least
one dose of namilumab and for whom PK parameters
could be calculated.
The post hoc analyses were conducted on the per
protocol population and excluded any patients with
major protocol criteria violations which could potentially
affect clinical efficacy (e.g., those who had used prohibited
concomitant medications, or those who were not on a
stable background dose of methotrexate or corticoste-
roids). Patients who increased their background cortico-
steroid dose during the study, or used any DMARDs other
than methotrexate, were classified as non-responders and,
where applicable, any subsequent data after the treatment
violation were excluded from the post hoc analyses.
Statistical analyses, which were primarily descriptive,
were undertaken using a statistical software program
(SAS system, version 9.2, SAS Institute, Inc., Cary NC,
USA). Namilumab plasma concentration data were
analyzed in WinNonlin (Phoenix® WinNonlin® version
6.3, Certara Inc., St. Louis, MO, USA) by non-
compartmental analysis using a plasma model with
extravascular dose type and the actual sampling time.
DAS28 (CRP and ESR) data are expressed as mean
(standard deviation) changes from baseline. Differences
between namilumab (both doses combined) and placebo
in the mean change from baseline in DAS28-CRP were
determined, along with 95% confidence intervals (CI), at
each visit. The rationale for this analysis was to assume
that both doses would perform better than placebo and
that the comparison with placebo of the two doses com-
bined would negate any potential cohort effect. An ana-
lysis of the DAS28-CRP profile (area under the curve;
AUC) was performed by determining the time-adjusted
mean change from baseline; comparisons to placebo
were tested using a Wilcoxon test. Improvements in
DAS28-ESR were defined according to European League
Against Rheumatism (EULAR) response criteria [36].
Results
Patients
A total of 24 patients were enrolled at 10 sites (2 in The
Netherlands, 4 in Bulgaria, and 4 in Spain). The first
patient was randomized March 2011, the last patient
was enrolled April 2013, and the last patient visit was
August 2013. Patient demographics and baseline charac-
teristics are shown in Table 1. Thirteen patients were
included in cohort 1 (8 randomized to namilumab
150 mg and 5 to placebo) and 11 were included in co-
hort 2 (7 randomized to namilumab 300 mg and 4 to
placebo). The median age was 59 years (range 29–75),
most patients were female (71%), and almost all patients
were white (96%). Mean baseline DAS28-ESR was 4.7;
disease activity was moderate and similar across treat-
ment groups. A total of 22 patients completed the
study (2 patients discontinued: 1 patient randomized
to placebo in cohort 1 [due to patient withdrawal]
and 1 patient randomized to namilumab 300 mg in
cohort 2 [due to the patient leaving the country];
(Additional file 2: Figure S2). Protocol amendments
did not impact data or study outcome.
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Safety
A total of 49 treatment-emergent AEs (TEAEs) were
reported in 14 patients (58%) (Table 2). The percent-
age of patients who had any TEAE was similar
between the treatment groups (placebo: 56%; namilu-
mab 150 mg: 63%; namilumab 300 mg: 57%). The
most frequent TEAEs were nasopharyngitis (n = 4;
17%), exacerbation or worsening of RA (n = 3; 13%),
musculoskeletal pain (n = 2; 8%), and increased blood
creatine phosphokinase (n = 2; 8%). Two serious
TEAEs were reported in the namilumab 150 mg
group. One was in a 61-year-old female smoker who
received three doses of namilumab and was diag-
nosed with severe non-small cell lung cancer
14 months after the last dose; this was the only
reported severe TEAE. The other serious TEAE was
in a 61-year old male with a history of coronary
artery stenosis and abnormal ECG, who received and
tolerated three doses of namilumab, and was diag-
nosed with mild coronary artery stenosis following a
routine ECG test on the day of the second dose.
Both serious TEAEs were considered unrelated to
namilumab. Five TEAEs were considered to be treat-
ment related: 3 in the placebo group (increased
blood creatine phosphokinase, bradycardia, and som-
nolence) and 1 in each namilumab group (150 mg:
increased alanine aminotransferase; 300 mg: increased
blood creatine phosphokinase). These were consid-
ered non-serious and did not lead to study discon-
tinuation or changes in study medication. There were
no deaths reported during this study.
PK
Namilumab plasma concentrations following three con-
secutive single subcutaneous injections of namilumab
(150 or 300 mg), administered 2 weeks apart, were
quantifiable for 84 days (last PK sampling time point).
The PK-evaluable population included all 8 patients in
the namilumab 150 mg group and 7 patients in the
namilumab 300 mg group.
The dose-normalized geometric mean plasma concen-
tration–time profiles are shown in Fig. 1. The PKs of
namilumab were linear and typical of an IgG1 monoclo-
nal antibody administered subcutaneously. The max-
imum observed plasma concentration (Cmax) was
reached at 5 to 6 days (Tmax) after the first and third
injection. Mean terminal half-life (t1/2) values were
approximately 3 weeks. The dose-normalized exposure
was similar for both groups. Anti-namilumab antibodies
were not detected in any patient.
PD
GM-CSF/namilumab complexes increased over time
reaching its maximum on day 43 for the 150 mg group
and on day 56 for 300 mg group, respectively. At the end
of the trial, levels were still above baseline for both groups.
There were no significant or consistent changes in per-
ipheral blood cytokines or pro-inflammatory markers,
including: interleukin-1 (IL-1), IL-6, IL-8, monocyte
chemotactic protein-1 (MCP-1), tumor necrosis factor
alpha (TNF-α), vascular endothelial growth factor
(VEGF) or matrix metalloproteinase 3 (MMP-3), related
to namilumab administration (data not shown).
Table 1 Baseline patient demographics and disease characteristics (safety population)
Placebo (n = 9) Namilumab 150 mg (n = 8) Namilumab 300 mg (n = 7) Total (N = 24)
Gender, n (%)
Female 6 (67) 5 (63) 6 (86) 17 (71)
Male 3 (33) 3 (38) 1 (14) 7 (29)
Race, n (%)
White 9 (100) 7 (88) 7 (100) 23 (96)
Black 0 1 (13) 0 1 (4)
Age, yearsa 56 (29–65) 59 (43–65) 59 (36–75) 59 (29–75)
BMI, kg/m2b 27.37 (2.246) 24.69 (2.471) 28.30 (1.778) 26.75 (2.607)
Disease duration, years 3.3 (0.9–10.9) 4.9 (1.7–19.0) 5.2 (3.0–9.3) 4.4 (0.9–19.0)
DAS28-ESRb 4.8 (0.41) 4.9 (0.35) 4.4 (0.59) 4.7 (0.48)
DAS28-CRPb 4.4 (0.82) 4.2 (0.52) 4.0 (0.62) 4.2 (0.65)
ESR, mm/hourb 31 (11.91) 28 (5.56) 23 (8.06) 28 (9.31)
CRP, mg/literb 21 (22.64) 8 (6.75) 12 (10.44) 13 (15.43)
TJCb (0–68) 8.7 (5.45) 9.1 (6.92) 9.6 (4.69) 9.1 (5.55)
SJCb (0–66) 5.0 (5.41) 4.3 (2.38) 6.1 (5.30) 5.1 (4.45)
The eligibility criteria allowed patients with previous biological therapy into the study, however, all of patients enrolled into the PRIORA study were biologic naive
BMI body mass index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, SD standard deviation, SJC swollen joint count, TJC tender joint count
aMedian (range); bmean (SD)
Huizinga et al. Arthritis Research & Therapy  (2017) 19:53 Page 4 of 10
Clinical efficacy
Efficacy was an exploratory objective using DAS44-ESR
and ACR20 assessment. In an initial analysis, mean and
median DAS44-ESR showed a general decrease from
baseline in all treatment groups including placebo. On
days 27 and 43 (2 weeks after the last namilumab dose),
the 300 mg namilumab group had the most pronounced
decrease (mean DAS44 reduction: 0.995 and 0.852, re-
spectively) compared with the placebo group (mean
DAS44 reduction: 0.383 and 0.469, respectively). Mean
DAS44 reduction from baseline in the 150 mg namilu-
mab group was 0.798 on day 27 and 0.873 on day 43.
From day 56 (4 weeks after the last namilumab dose),
mean DAS44 reduction from baseline started decreasing
in the 150 mg namilumab group; however, in contrast,
there was a more pronounced response in the placebo
group. This pronounced response in the placebo group
was influenced by 2 patients. One in particular had
severe disease activity up to day 43 (DAS44 5.24 at
day 43), and showed a fast response (DAS44 de-
creased to 1.43 at day 56) after receiving high-dose
methylprednisolone, sulfasalazine, and hydroxychloro-
quine in addition to methotrexate. Mean DAS44
reduction from baseline increased in the 300 mg namilu-
mab group until day 56 and, thereafter, remained almost
unchanged until day 99.
The initial analysis also demonstrated that in all treat-
ment groups, including placebo, and at all visits from
day 13, there were patients who met the ACR20 criteria.
Although ACR20 was higher numerically in the 300 mg
namilumab group compared with the placebo group at
all visits, the results were inconclusive in terms of a clear
efficacy signal because of a high ACR20 response in the
placebo group, especially after day 43.
The post hoc analysis assessed DAS28 in a per proto-
col population in order to undertake an additional inves-
tigation of the clinical significant effects of namilumab
on the signs and symptoms of RA using the DAS28, SJC
(66 joints), TJC (68 joints), and patient outcome mea-
sures (VAS scores). These analyses were conducted on
all subjects in PRIORA and on a predefined subset of
patients who were free from major protocol criteria vio-
lations, which could potentially affect clinical efficacy.
Three patients were excluded: 1 patient in the namilu-
mab 150 mg group and 1 patient in the placebo group
due to changes in dose of corticosteroids and/or metho-
trexate prior to randomization; and 1 patient in the
placebo group due to receiving a high dose of cortico-
steroid (intramuscular methylprednisolone 120 mg) and
an additional DMARD (sulfasalazine) during the study,
as well as changes in dose of corticosteroids prior to
randomization. Baseline patient demographics and dis-
ease characteristics of the per protocol population are
shown in Table 3.
Two weeks after the last dose (day 43), reductions in
DAS28 (ESR and CRP) and joint counts were greater
with namilumab (150 and 300 mg) compared with pla-
cebo. Namilumab (150 and 300 mg), compared with pla-
cebo, was associated with greater improvements in
DAS28-CRP as early as day 27; these improvements
were maintained until the end of the study (day 99;
Fig. 2) specifically for the 300 mg namilumab cohort. A
significantly greater improvement in DAS28-CRP was
shown with namilumab (150 and 300 mg groups
combined) compared with placebo at day 43 (−0.779 vs
−0.106, p = 0.0117) and also day 99 (−0.997 vs −0.320, p
= 0.0154), as measured by the time-adjusted mean
change from baseline (per protocol subset), (Fig. 2). Indi-
vidually, the time-adjusted mean change of DAS28-CRP
Table 2 TEAEs in >1 patient by system organ class










Preferred term, na (%)
Any TEAE 5 (56) 5 (63) 4 (57) 14 (58)
Musculoskeletal and
connective tissue disorders
3 (33) 3 (38) 0 6 (25)
Exacerbation/worsening
of RA
2 (22) 1 (13) 0 3 (13)
Musculoskeletal pain 0 2 (25) 0 2 (8)
Pain in extremity 1 (11) 0 0 1 (4)
Muscular weakness 1 (11) 0 0 1 (4)
Laboratory investigations
(total)b
1 (11) 3 (38) 2 (29) 6 (25)
Infections and infestations 2 (22) 3 (38) 0 5 (21)
Nasopharyngitis 2 (22) 2 (25) 0 4 (17)
Urinary tract infection 0 1 (13) 0 1 (4)
Gastrointestinal disorders 0 2 (25) 1 (14) 3 (13)
Abdominal pain, upper 0 1 (13) 0 1 (4)
Diarrhea 0 1 (13) 0 1 (4)
Abdominal pain 0 0 1 (14) 1 (4)
Cardiac disorders 1 (11) 1 (13) 0 2 (8)
Bradycardia 1 (11) 0 0 1 (4)
Coronary artery stenosis 0 1 (13) 0 1 (4)
General disorders and
administrative site conditions
1 (11) 0 1 (14) 2 (8)
Chest discomfort 1 (11) 0 0 1 (4)
Chest pain 0 0 1 (14) 1 (4)
Influenza-like illness 0 0 1 (14) 1 (4)
Nervous system disorders 1 (11) 1 (13) 0 2 (8)
Paresthesia 0 1 (13) 0 1 (4)
Somnolence 1 (11) 0 0 1 (4)
Renal and urinary disorders 1 (11) 0 1 (14) 2 (8)
Dysuria 1 (11) 0 0 1 (4)
Nephrolithiasis 0 0 1 (14) 1 (4)
RA rheumatoid arthritis, TEAE treatment-emergent adverse event
aNumber of patients with ≥1 event in the category; bof which: increased
blood creatine phosphokinase (n = 2; 8%)
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from baseline for namilumab 150 mg and namilumab
300 mg at day 43 was −0.940 vs −0.106 (p = 0.0140) and
−0.620 vs −0.106 (p = 0.0734), respectively, and at day 99
was −1.165 vs −0.320 (p = 0.0140) and −0.829 vs −0.320
(p = 0.1014), respectively. The differences in mean
DAS28-CRP changes from baseline between namilumab
(150 and 300 mg groups combined) and placebo favored
namilumab at all time points (Fig. 3). DAS28-ESR
followed a similar pattern, although the data were more
variable. On day 56 (4 weeks after the last dose), a
greater proportion of patients had a DAS28-ESR re-
sponse (>1.2 decrease from baseline) with namilumab
(71% [n = 10/14]; both groups combined) compared with
placebo (29% [n = 2/7]). The DAS28-ESR response rate
was 86% (n = 6/7) in the namilumab 150 mg group and
57% (n = 4/7) in the namilumab 300 mg group. SJCs and
TJCs showed a greater decrease over time in patients
who received namilumab compared with placebo. The
observed improvement in SJCs and TJCs with namilu-
mab versus placebo was apparent from the first dose
and maintained at all subsequent time points (Additional
file 3: Figure S3). Improvements in patient-reported out-
come measures, including patient global assessment of
disease activity and assessment of pain were also higher
in the namilumab-treated groups than the placebo
group.
Discussion
This phase 1b study assessed the safety, tolerability, PK,
PD, and preliminary efficacy of repeated subcutaneous
injections of namilumab in patients with mild-to-
moderate RA on stable doses of methotrexate. Namilu-
mab subcutaneous injections (150 and 300 mg) given
every 2 weeks for 4 weeks were generally well tolerated
with an acceptable safety profile. Incidence of TEAEs
was similar between treatment groups and reported AEs
were mostly mild in intensity and similar between the
namilumab and placebo cohorts. The majority of TEAEs
with moderate intensity were reported in patients receiv-
ing placebo. The only TEAE of severe intensity was a
Fig. 1 Dose-normalized geometric mean plasma concentration–time profile of namilumab (error bars show ± 1 SD). SD standard deviation
Table 3 Baseline disease characteristics of the per protocol population
Mean (SD) Placebo (n = 7) Namilumab 150 mg (n = 7) Namilumab 300 mg (n = 7) Total (N = 21)
DAS28-ESR 4.7 (0.33) 4.9 (0.35) 4.4 (0.59) 4.7 (0.47)
DAS28-CRP 4.0 (0.35) 4.4 (0.33) 4.0 (0.62) 4.1 (0.46)
ESR, mm/hour 31.3 (7.43) 27.7 (5.94) 23.0 (8.06) 27.3 (7.66)
CRP, mg/liter 16.4 (25.09) 9.1 (6.42) 11.5 (10.44) 12.2 (14.91)
TJC (0–68) 6.6 (2.15) 10.0 (6.98) 9.6 (4.69) 8.7 (5.00)
SJC (0–66) 3.4 (1.4) 4.7 (2.14) 6.1 (5.3) 4.8 (3.42)
PGA for pain 54.6 (14.9) 58.4 (21.1) 50.1 (16.7) 54.3 (17.5)
PGA of DAS 42.4 (21.1) 59.9 (19.3) 43.3 (16.4) 39.5 (18.9)
CRP C-reactive protein, DAS disease activity score, ESR erythrocyte sedimentation rate, PGA patient global assessment, SD standard deviation, SJC swollen joint
count, TJC tender joint count
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non-small cell lung cancer that occurred in a 61-year-
old female smoker who was diagnosed 14 months after
the last dose of namilumab (150 mg); furthermore, it
was not considered to be related to the study medica-
tion. No drug reactions, allergic reactions or injection-
site reactions were reported during the trial. The safety
profile observed for namilumab in our study was con-
sistent with previously reported clinical experience using
anti-GM-CSF antibodies. In addition, in accordance
with data from a preclinical, multiple-dose toxicology
study in monkeys [34], there was no indication of im-
munogenicity to repeated subcutaneous administration
of namilumab in this study, as indicated by the lack
of anti-namilumab antibodies in blood samples taken
from patients.
Autoantibodies against GM-CSF have been associated
with the development of idiopathic autoimmune pul-
monary alveolar proteinosis (PAP), a rare but potentially
serious lung disease, in which abnormal accumulation of
pulmonary surfactant protein occurs within the alveoli
due to insufficient clearance by GM-CSF-starved macro-
phages [37, 38]. Because of this association, there is a
theoretical risk of developing PAP when using thera-
peutic antibodies that target GM-CSF. Accordingly,
patients with severe pulmonary diseases were ex-
cluded from the study and pulmonary function tests
were employed in this study as part of a safety moni-
toring plan, even though the risk of developing PAP
after short-term repeated administration of namilu-
mab was considered very low. Importantly, no abnor-
mal respiratory signals were detected in our study. A
recently reported, long-term, phase 2a, open-label ex-
tension study also demonstrated an acceptable safety
profile with no significant pulmonary signals when
mavrilimumab was administered over 74 weeks to pa-
tients with moderate-to-severe RA on a stable dose of
methotrexate [39].
In the PK/PD analyses, namilumab plasma concentra-
tions following three consecutive single subcutaneous
injections of 150 or 300 mg showed typical absorption
and elimination kinetics associated with a human IgG1
antibody administered via this route [40]. The PK of
namilumab was linear with a Tmax of 5–6 days and a
t1/2 of approximately 3 weeks. The PD analyses
showed an increase in GM-CSF/namilumab complexes
after namilumab injections, which was consistent with
the proposed mode of action for namilumab [32].
Further PD analyses showed no changes in peripheral
blood cytokines or other markers of inflammation fol-
lowing namilumab administration. A similar lack of
effect on pro-inflammatory cytokines was reported for
the anti-GM-CSF antibody, MOR103 [30]. In contrast,
mavrilimumab has been shown to induce dose-
dependent decreases in biomarkers (such as IL-6,
MMP-3, serum amyloid A [SAA] and YKL-40) when
measured with a multi-biomarker disease activity
(MBDA, Vectra DA) score [27], but MBDA was not
assessed in the PRIORA study. These apparently con-
flicting results, as compared with the present study,
could be a consequence of the differing sensitivities
of the assays used or may reflect differences in
systemic inflammation between the two patient
Fig. 2 Change from baseline in DAS28-CRP with namilumab
compared with placebo. *Error bars show upper SE for placebo
and lower SE for namilumab. DAS disease activity score, CRP
C-reactive protein, SE standard error
Fig. 3 Forest plot showing the difference from placebo with
namilumab for DAS28-CRP mean change from baseline.
CI confidence interval, CRP C-reactive protein, DAS disease activity score
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populations. Alternatively, it may be that GM-CSF
blockade with namilumab does not induce changes in
peripheral markers of inflammation. Larger studies
are required to further investigate the effect of nami-
lumab on biomarkers of disease activity.
The clinical efficacy analyses were exploratory and
were assessed initially using DAS44-ESR from all pa-
tients. Although a more prominent reduction in DAS44-
ESR from baseline was observed in namilumab-treated
patients compared with placebo, particularly in those
who received the 300 mg dose, no meaningful or defini-
tive efficacy conclusions could be drawn from the initial
analysis. The lack of a marked treatment effect on
DAS44-ESR, particularly during the post-dose follow-up
period, may have been a consequence of changes in the
background RA treatment regimen and/or the effect of
decreasing acute phase proteins in the placebo group
(baseline CRP was most pronounced in this group and
therefore may have contributed to the high placebo
response). At the same time, the effects of active treat-
ment were not sustained in the two namilumab-treated
cohorts. Nonetheless, a post hoc, per protocol efficacy
analysis revealed a strong efficacy signal for namilumab
on the signs and symptoms of RA based on its effect on
DAS28-CRP, SJCs, and TJCs. This analysis, which was
based on a statistical analysis plan incorporating add-
itional clinically relevant endpoints, included 21 patients
without major protocol violations (1 patient on namilu-
mab 150 mg and 2 patients on placebo were excluded).
The analysis showed that patients receiving namilumab
(150 and 300 mg) had greater improvements from base-
line in DAS28-CRP, TJCs, and SJCs compared with
patients who received placebo. These improved efficacy
outcomes with namilumab were reported as early as
week 2, as has been reported for mavrilimumab [26–29].
Considering the size of our study, it was an appropriate
approach to analyze the DAS28-CRP profile (AUC) in
the 150 and 300 mg namilumab combined group versus
placebo. A significant improvement in DAS28-CRP was
shown with the namilumab combined group compared
with placebo at day 43 (p = 0.0117) and also 8 weeks
after last dosing at day 99 (p = 0.0154); these findings
provide further support demonstrating the signal efficacy
of namilumab in RA patients. Individual treatment com-
parisons to placebo are more difficult to interpret due to
the small subject numbers and possible cohort effect;
however the 150 mg namilumab group was statistically
different to placebo (p = 0.0140) and not the 300 mg
group (p = 0.1014). Furthermore, the effect of namilu-
mab on DAS28-CRP was more prolonged in those
patients who responded to the 300 mg dose com-
pared to those in the 150 mg group, likely reflecting
the greater and longer systemic PK exposure at the
higher dose.
It was clear from the post hoc efficacy analysis that
not all namilumab-treated patients responded well to
treatment. Exploratory analyses showed that the lack
of effect of namilumab in these poorly responding
patients could not be explained by differences in
baseline characteristics or PK exposure compared
with patients who exhibited moderate or strong
responses (data not shown). Exploratory studies are
ongoing aimed at identifying biomarkers that can be
used to identify a target patient population who will
respond to namilumab.
Conclusions
The results of this study suggest that namilumab (150
and 300 mg) is generally well tolerated and shows signs
of clinical activity in patients with mild-to-moderate RA.
There are some limitations of this study; it was an early
phase, short-duration study with a small number of
patients in each treatment group, with some differ-
ences in baseline characteristics between groups.
Despite these limitations, this study showed a strong
signal of efficacy and supports the further develop-
ment of namilumab for the treatment of RA. A phase
2 dose-finding study of namilumab in combination
with methotrexate (NEXUS; NCT02379091) is now
ongoing in patients with moderate-to-severe RA who
have responded inadequately to methotrexate or an
anti-tumor necrosis factor inhibitor.
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